Bausch + Lomb Corporation (BLCO) operates as a significant entity within the vision care sector, fielding a diverse range of products across its three core segments: vision care, surgical, and ophthalmic pharmaceuticals. The company boasts an extensive portfolio, featuring over 100 products, positioning it with a substantial offering of eye care prescriptions. Recent market activity shows the stock trading at $16.52, a slight dip of -0.12% from its previous close, with a recent surge of +3.89% noted.
The company's market position is underpinned by its substantial commercial strength in both contact lens and consumer eye care products, anticipated to fuel consistent growth. Its surgical division encompasses a suite of intraocular lenses and equipment for cataract and vitreoretinal surgeries, while its ophthalmic pharmaceuticals arm includes treatments for various eye conditions such as Xipere, Vyzulta, and Lotemax.
Read More: Nvidia Stock Rises as UAE Agrees to Invest in US for Chip Exports
Financial Footing and Market Perception
Recent financial indicators present a mixed picture. The company's Price-to-Earnings (P/E) ratio (TTM) stands at -16.23, with a forward P/E (NTM) of 21.54. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for the Trailing Twelve Months (TTM) reached $609.00 million. However, the Return on Equity (ROE) for the TTM is -5.57%, and the Net Margin (TTM) is -6.90%. Revenue for the TTM totaled $5.101 billion, with a Gross Margin of 59.81%. The Debt-to-Equity ratio is reported at 78.82%.
The stock has seen a 3.89% price increase, reaching $16.54 from its previous close, a move of $0.62. It is currently trading within its 52-week range, having hit a high of $18.92 on February 25, 2026, and a low of $10.45 on April 30, 2025. The average stock price over the last 52 weeks is $14.91. Analysts' ratings show a spectrum of views, with some indications pointing towards "Strong buy" and "Sell" recommendations aggregated from professional assessments.
Read More: Australia Recalls Sunscreens Not Meeting SPF 50+ Claims
Corporate Developments and Product Pipeline
Bausch + Lomb has recently been active with corporate announcements, including changes to its Board of Directors and updates regarding product clearances and launches. The company has received FDA 510(k) clearance for its Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update, and has launched preloaded enVista Envy™ intraocular lenses in Europe. Further developments include the announcement of new scientific data and educational events at the American Society of Cataract and Refractive Surgery Annual Meeting.
The company has also provided forward-looking financial information, with a first-quarter 2026 earnings release scheduled for April 29, and fourth-quarter and full-year 2025 results and 2026 guidance also on the horizon. Recent findings published in Ophthalmology and Therapy suggest a lifestyle-driven rise in ocular redness, highlighting the role of their product LUMIFY®. The company also reported positive 24-month U.S. data on its ELIOS™ System for glaucoma treatment.
Read More: Jo Malone sued by Estee Lauder for using her name with Zara
Operational Framework
Bausch + Lomb operates internationally, with a presence in key markets including the United States, China, France, Japan, Germany, the United Kingdom, and Canada, among others. It functions as a subsidiary of Bausch Health Companies Inc. The company's product line extends to consumer goods such as Biotrue® and Renu® multi-purpose solutions, Biotrue® ONEday daily disposable contact lenses, Lumify® redness reliever eye drops, PreserVision® AREDS 2 formula eye vitamins, and Vyzulta®.
Market makers and ECNs participate in trading on a voluntary basis. Investors are advised that pre-market (4 a.m. to 9:30 a.m. ET) and after-hours (4 p.m. to 8 p.m. ET) trading sessions may offer lower liquidity and potentially different pricing. Reliance on limit orders is recommended for participants in these off-exchange trading periods.
